Expression of Notch pathway components (Numb, Itch, and Siah-1) in colorectal tumors: A clinicopathological study

Table 4 Mean and median values of relative gene expression levels of Notch-1, Numb, Itch and Siah-1 in tumors with different clinicopathological parameters (qPCR analysis)

Parameters	n	Notch-1		Numb		Itch		Siah-1
		mean ± SD1	Median	mean ± SD	Median	mean ± SD	Median	mean ± SD	Median
Age
64 ± 12.35 ≥	24	11.23 ± 5.23	-1.18	1.08 ± 1.03	-1.03	1.73 ± 2.34	-1.22	0.81 ± 0.32	-1.22
64 ± 12.35 <	26	9.20 ± 4.34	1.67	3.28 ± 4.32	-2.26	3.35 ± 1.64	1.99	0.85 ± 0.42	-2.99
Gender
Female	17	10.21 ± 6.02	1.38	1.74 ± 1.34	-2.43	1.93 ± 1.34	1.35	0.23 ± 0.03	-3.19
Male	33	10.58 ± 5.03	1.67	3.42 ± 3.42	4.67	2.70 ± 2.10	-1.21	2.00 ± 0.93	-1.22
Localization
Caecum	8	13.10 ± 5.23	12.39	1.17 ± 1.45	1.31	1.85 ± 1.62	2.43	2.40 ± 1.11	0.41
Colon	16	7.99 ± 7.32	-1.50	2.60 ± 2.34	1.20	3.33 ± 2.03	2.30	0.26 ± 0.23	-2.56
Sigmoid	10	15.03 ± 6.23	20.79	3.69 ± 2.45	3.03	-1.03 ± 0.3	-1.75	-0.77 ± 0.22	-1.49
Rectum	16	8.37 ± 3.41	1.16	1.72 ± 1.65	-2.96	2.63 ± 1.22	1.67	1.62 ± 0.51	-3.48
Differentiationa
WD	18	3.92 ± 2.45	-3.08	6.64 ± 3.46	9.92	5.26 ± 2.42	7.05	3.67 ± 1.53	-1.22
MD	15	9.85 ± 4.46	21.67	1.26 ± 1.04	-2.26	-1.20 ± 0.84	-2.41	-1.66 ± 0.66	-3.24
PD	17	17.28 ± 9.03	22.54	-3.62 ± 1.81	-4.45	-0.03 ± 0.01	-1.86	-1.91 ± 0.65	-4.21
Invasion
T1	7	5.39 ± 5.93	-7.70	9.40 ± 4.72	14.62	10.04 ± 5.80	12.06	2.75 ± 1.36	-3.89
T2	10	10.01 ± 6.82	4.45	3.63 ± 2.45	-3.06	1.41 ± 0.56	-2.26	1.43 ± 0.92	-3.86
T3	23	11.38 ± 7.02	1.67	1.63 ± 1.85	-2.26	1.39 ± 0.8	-1.91	1.87 ± 0.23	-1.16
T4	10	11.75 ± 6.88	9.59	-2.40 ± 2.03	-3.39	-1.65 ± 0.3	-1.51	-3.51 ± 1.48	-2.94
LNMa
Absent	17	2.45 ± 2.67	-4.54	8.66 ± 4.82	13.40	5.91 ± 2.20	7.84	5.77 ± 2.81	-1.16
Present	33	15.17 ± 6.89	19.90	-1.57 ± 1.24	-2.35	-1.07 ± 0.51	-1.65	-2.19 ± 1.08	-3.54
Lymphatic invasion
Absent	37	10.84 ± 6.36	1.67	1.54 ± 3.42	-2.26	1.68 ± 0.83	1.35	0.45 ± 0.23	-3.19
Present	13	8.92 ± 5.32	1.38	4.51 ± 3.83	3.79	3.67 ± 1.43	1.38	1.90 ± 0.92	-1.35
Vascular invasion
Absent	42	11.77 ± 8.43	1.67	1.92 ± 1.65	-2.26	1.44 ± 0.96	1.07	-0.48 ± 0.28	-3.22
Present	8	12.96 ± 7.32	-2.98	9.63 ± 5.32	13.13	6.17 ± 3.02	5.66	7.77 ± 3.82	5.50
Perineural invasion
Absent	31	8.92 ± 5.32	-1.01	2.58 ± 2.48	-2.26	2.86 ± 1.32	2.00	1.22 ± 0.32	-3.22
Present	19	12.65 ± 6.02	17.79	1.87 ± 1.82	2.27	1.17 ± 0.61	-1.21	0.20 ± 0.80	5.50
Stagea
1 + 2	24	4.45 ± 4.02	-9.81	12.85 ± 5.63	7.53	5.24 ± 2.31	6.89	1.24 ± 0.51	-1.64
3 + 4	26	15.78 ± 7.94	-8.25	9.72 ± 4.63	-2.29	-1.61 ± 0.22	-1.88	0.21 ± 0.03	-2.42
Distant metastasis
Absent	26	9.83 ± 7.34	-1.18	3.42 ± 1.86	1.99	3.17 ± 1.24	1.77	0.99 ± 0.23	-2.45
Present	24	10.89 ± 6.53	1.67	1.11 ± 1.02	-2.86	1.14 ± 0.82	-1.15	0.66 ± 0.23	-2.02
Survival (mo)a
60.62 ± 26.68 ≥	26	17.16 ± 6.04	21.22	-5.47 ± 2.24	-4.90	-2.03 ± 1.06	-2.47	-4.63 ± 2.07	-4.05
60.62 ± 26.68 <	24	2.95 ± 2.02	-5.33	10.75 ± 5.21	13.13	6.78 ± 2.83	8.51	6.76 ±	3.15

^aP < 0.05.

¹Fold increase (2^-∆∆Ct). WD: Well-differentiated; MD: Moderately differentiated; PD: Poorly differentiated; LNM: Lymph node metastasis.